Trial Profile
An Open Label, Randomized, comparison of the Immunogenicity and Safety of Wockhardts Human Insulin Basal Bolus Regimen {Intensified Conventional Insulin Therapy with Soluble Insulin and Isophane Insulin (Wosulin R, Wosulin N and Wosulin 70/30)} with the Novo Nordisk?s yeast based Human Insulin Basal Bolus Regimens, marketed in United States (Novolin R, Novolin N and Novolin 70/30) in Type 1 Diabetics.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin suspension isophane (Primary) ; Insulin suspension isophane/insulin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- 28 Mar 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 04 Mar 2013 Planned End Date changed from 1 Mar 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 24 Jan 2013 Planned End Date changed from 1 Oct 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov.